Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Arixtra (fondaparinux) vs. lovenox (enoxaparin) in prevention of deep vein thrombosis in acute medically ill, non-surgical patients.

Trial Profile

Arixtra (fondaparinux) vs. lovenox (enoxaparin) in prevention of deep vein thrombosis in acute medically ill, non-surgical patients.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Dec 2017

At a glance

  • Drugs Enoxaparin sodium (Primary) ; Fondaparinux sodium (Primary)
  • Indications Deep vein thrombosis
  • Focus Adverse reactions
  • Acronyms BRiEF
  • Most Recent Events

    • 08 Jul 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 13 Dec 2007 Status changed from initiated to recruiting.
    • 03 Sep 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top